HOME >> BIOLOGY >> NEWS
OXiGENE announces phase II clinical trial of lead anti-tumor compound in thyroid cancer

te, and reinforces our position as the leader in this emerging area of cancer therapy."

"The pre-clinical and early clinical experience of CA4P makes the compound extremely well-suited for study in Phase II," said the trial's lead investigator, Scot C. Remick, M.D., Associate Professor of Medicine and International Health at University Hospitals of Cleveland and Case Western Reserve University School of Medicine. "Based on our Phase I experience, we are very pleased to continue development of this compound for the treatment of ATC. This clinical trial offers a unique opportunity to investigate a novel anti-tumor treatment, and to potentially establish CA4P as a new therapy."

In addition to the trial announced today, a Phase Ib trial of CA4P is underway at the University of Pennsylvania's Presbyterian Medical Center, where researchers are studying the VTA in combination with a chemotherapy drug called Carboplatin.

CA4P attacks the vascular structure of solid tumors and other diseases characterized by the formation of aberrant blood vessels. The compound triggers a change in the shape of endothelial cells lining a tumor's blood vessels. This in turn blocks the flow of blood to the tumor, depriving it of oxygen and nutrients. The compound is a synthetic form of CA4, a natural substance found in the bark of the South African willow tree known as combretum caffrum. CA4 was identified and isolated in 1987 by Professor G. Robert Pettit, director of the Cancer Research Institute at Arizona State University.

"Our Phase II study represents an opportunity to assess the preliminary efficacy of CA4P in a specific indication," said Dai Chaplin, Ph.D., OXiGENE's chief scientific officer. "This is particularly exciting because our Phase I study resulted in a complete pathological response in a patient with the identical disease."


'"/>

Contact: Scott Solomon
ssolomon@investorrelations.com
617-542-5300
Sharon Merrill Associates, Inc.
23-Dec-2002


Page: 1 2

Related biology news :

1. OXiGENE launches significant expansion of its R&D program in ophthalmology
2. OXiGENE announces launch of ophthalmic clinical trial at The Johns Hopkins School of Medicine
3. OXiGENE announces commencement of Phase I/II clinical trial of Combretastatin A4 Prodrug
4. OXiGENE, foundation fighting blindness sign research agreement for phase I/II clinical trial
5. Secretary of Energy announces seven E.O. Lawrence Award Winners
6. Popular Science announces Third Annual Brilliant 10
7. The American Phytopathological Society announces 2004 awards
8. NSF announces six FIBR awards to tackle some of biologys most challenging questions
9. Protemix corporation announces discovery of way to repair hearts damaged by diabetes
10. JGI announces community sequencing program portfolio
11. APS announces the winners of its 2004 postdoctoral fellowship in physiological genomics

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/15/2016)... Dec. 14, 2016 "Increase in mobile transactions ... The mobile biometrics market is expected to grow from ... by 2022, at a CAGR of 29.3% between 2016 ... as the growing demand for smart devices, government initiatives, ... "Software component is expected to grow at a ...
(Date:12/8/2016)...  Singulex, Inc., the leader in Next Generation Immunodiagnostics ... license and supply agreement with Thermo Fisher Scientific, the ... access to Thermo Scientific BRAHMS PCT (Procalcitonin), a biomarker ... to diagnose systemic bacterial infection and sepsis and in ... in assessing the risk of critically ill patients for ...
(Date:12/7/2016)... 7, 2016   Avanade is helping Williams ... teams in history, exploit biometric data in order to ... maintain the competitive edge against their rivals after their ... Avanade has worked with Williams during the 2016 ... data (heart rate, breathing rate, temperature and peak acceleration) ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... NY (PRWEB) , ... January 18, 2017 , ... Researchers from a new study ... do not fall low enough after prostate cancer treatment, this indicates there is still remaining ... risk of mortality. , “ The PSA test has always been an indicator of whether ...
(Date:1/18/2017)... , ... January 18, 2017 , ... Thirty-six startup companies ... credits by the Pennsylvania Department of Community and Economic Development in 2016 as part ... located in the University City Keystone Innovation Zone and represent the highest number of ...
(Date:1/18/2017)... , Jan. 18, 2017 /PRNewswire/ - SQI ... sciences and diagnostics company that develops and commercializes ... ("SQI" or the "Company"), today announced that ... Inc. ("Kingsdale"), has resigned from its Board of ... changes to securities regulations that have limited both ...
(Date:1/17/2017)... , Jan. 17, 2017 The Global ... a CAGR of around 7.5% over the next ... Some of the prominent trends that the market ... of diseases & graft transplant surgeries and medical ... the market is categorized into immunomodulatory biomaterials, natural, ...
Breaking Biology Technology:
Cached News: